Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 4, 2005, Pages 337-343

  Behan, K ^a,b,c   Cutts, C ^a,d   Tett, S E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Queensland Rural Medical Support Agency   (Australia)

^c ALICE SPRINGS HOSPITAL   (Australia)

^d St Helen's Primary Care Trust   (United Kingdom)

Author keywords

COX 2 inhibitors; Non steroidal antiinflammatory drugs; Prescribing; Questionnaire; Rural

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; DOCTOR PATIENT RELATION; DRUG SAFETY; GENERAL PRACTITIONER; HUMAN; MEDICAL PRACTICE; MOTIVATION; PERCEPTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; QUESTIONNAIRE; RURAL AREA; URBAN AREA; AUSTRALIA; CLINICAL PRACTICE; COMPARATIVE STUDY; EPIDEMIOLOGY; HEALTH PERSONNEL ATTITUDE; RURAL POPULATION; URBAN POPULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATTITUDE OF HEALTH PERSONNEL; CYCLOOXYGENASE INHIBITORS; HEALTH CARE SURVEYS; HUMANS; MOTIVATION; PHYSICIAN'S PRACTICE PATTERNS; QUEENSLAND; RURAL POPULATION; URBAN POPULATION;

EID: 26944491902     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00648.x     Document Type: Article

References (30)

1. Monaghan MS, Galt KA, Turner PD et al. (2003) Student understanding of the relationship between the health professions and the pharmaceutical industry. Teaching and Learning in Medicine, 15, 14-20.
2. Majumdar SR, McAlister FA, Soumerai SB (2003) Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. American Journal of Medicine, 115, 467-472.
3. Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB (2003) Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Clinical therapeutics, 25, 273-284.
4. Cutts C, Tett S (2003) Doctors perceptions of the influences on their prescribing: a comparison of general practitioners based in rural and urban Australia. European Journal of Clinical Pharmacology, 58, 761-766.
5. Cutts C, Tett S (2003) Influence on doctor's prescribing: is geographical remoteness a factor? Australian Journal of Rural Health, 11, 124-130.
6. Mintzes B, Barer ML, Kravitz RL et al. (2002) Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. British Medical Journal, 324, 278-279.
7. Robertson J, Fryer JL, O'Connell DL, Smith AJ, Henry DA (2001) Personal formularies. An index of prescribing quality? European Journal of Clinical Pharmacology, 57, 333-341.
8. Gonul FF, Carter F, Petrova E, Srinivasan K (2001) Promotion of prescription drugs and its impact on physicians' choice behavior. Journal of Marketing, 65, 79-90.
9. Cutts C, Tett S, La Caze A (2003) A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. British Journal of Clinical Pharmacology, 54, 522-527.
10. Britt H, Miller G, Valenti L (2001) 'It's different in the bush' A comparison of general practice activity in metropolitan and rural areas of Australia 1998-2000. Canberra: Australian Institute of Health and Welfare, Report No.: AIHW Cat. No. GEP 6.: (General Practice Series No. 6).
11. Humphreys J, Jones J, Jones M et al. (2003) The influence of geographical location on the complexity of rural general practice activities. Medical Journal of Australia, 179, 416-420.
12. Behan K, Cutts C, Tett SE (2005) Uptake of new drugs in rural and urban areas of Queensland, Australia - the example of COX-2 inhibitors. European Journal of Clinical Pharmacology, 61, 55-58.
13. Anon (2002) Celecoxib: early Australian reporting experience. Australian Adverse Drug Reaction Advisory Committee Bulletin, 19, 6-7.
14. Gomez Cerezo J, Lubomirov Hristov R, Carcas Sansuan A, Vazquez Rodriguez J (2003) Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. European Journal of Clinical Pharmacology, 59, 169-175.
15. Malhotra S, Shafiq N, Pandhi P (2004) COX-2 inhibitors: a CLASS act or Just VIGORously promoted. Medscape General Medicine, 6, 6.
16. Singh D (2004) Merck withdraws arthritis drug worldwide. British Medical Journal, 329, 816.
17. Couzin J (2004) Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science, 306, 384-385.
18. Krum H, Liew D, Aw J, Haas S (2004) Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert Reviews in Cardiovascular Therapy, 2, 265-270.
19. Cutts C, La Caze A, Tett S (2003) Audit of selective and non-selective non-steroidal anti-inflammatory drug use in rural general practice. Journal of Pharmacy Practice and Research, 33, 70-73.
20. Cutts C, Tett SE (2005) Do rural consumers expect a prescription from their GP visit? Investigation of patients' expectations and doctors prescribing decisions in rural Australia. Australian Journal of Rural Health, 13, 43-50.
21. Shaughnessy AF, Bucci KK (1997) Drug samples and family practice residents. Annals of Pharmacotherapy, 31, 1296-1300.
22. Liaw ST, Pearce CM, Chondros P, McGrath BP, Piggford L, Jones K (2003) Doctors' perceptions and attitudes to prescribing within the Authority Prescribing System. Medical Journal of Australia, 178, 203-206.
23. Leung GM, Ho LM, Chan MF, Jm MJ, Wong FK (2002) The effects of cash and lottery incentives on mailed surveys to physicians: a randomized trial. Journal of Clinical Epidemiology, 55, 801-807.
24. VanGeest JB, Wynia MK, Cummins DS, Wilson IB (2001) Effects of different monetary incentives on the return rate of a national mail survey of physicians. Medical Care, 39, 197-201.
25. Bell RA, Kravitz RL, Wilkes MS (2000) Direct-to-consumer prescription drug advertising, 1989-1998. A content analysis of conditions, targets, inducements, and appeals. Journal of Family Practice, 49, 329-335.
26. McKenna M, O'Dwyer E (2001) Access to arthritis medicine restricted. Courier Mail, Brisbane: Australia Newspaper, 24 May.
27. Langton PE, Hankey GJ, Eikelboom JW (2004) Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. Medical Journal of Australia, 181, 524-525.
28. Prosser H, Almond S, Walley T (2003) Influences on GPs' decision to prescribe new drugs - the importance of who says what. Family Practice, 20, 61-68.
29. Jones M, Greenfield S, Bradley C (2001) Prescribing new drugs: qualitative study of influences on consultants and general practitioners. British Medical Journal, 323, 1-7.
30. Kerr S, Mant A, Horn F, McGeechan K, Sayer G (2003) Lessons learned from the large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Medical Journal of Australia, 179, 403-407.